Novartis Licenses Experimental Tuberculosis Drugs to TB Alliance in Exclusive Deal

By Admin
Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development for compounds to fight tuberculosis (TB...

Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development for compounds to fight tuberculosis (TB) that have been discovered at the Novartis Institute for Tropical Diseases (NITD).

According to a news release issued this morning, Aug. 20, NITD will fully transfer its TB research and development program to TB Alliance, which will take financial and operational responsibility for continued research, development, approval and distribution of compounds in the portfolio. Included in the transfer is a class of drugs called indolcarboxamides that are active against drug sensitive and multi-resistant strains of TB.

“TB is one of the scourges of the developing world and new medicines are desperately needed to combat its continued spread,” said Mark C. Fisherman, President of Novartis Institutes for BioMedical Research. “TB Alliance is well placed to take our discoveries and compounds through development for the benefit of patients with TB.”

There are more than 8.6 million cases of tuberculosis each year, with more than 1.3 million deaths reported annually, according to the World Health Organization.

Novartis has collaborated with major players, including TB Alliance, in the past and believes TB Alliance has the best combination of expertise, capacity and strategic interest to develop new agents and regimens for TB.

“Our long-standing partnership with Novartis gives us confidence in the scientific underpinnings of the TB portfolio,” said Mel Spigelman, MD, President and CEO of TB Alliance. “We look forward to advancing the most promising compounds into the clinic to meet the urgent need for new TB treatments.” 

Share

Featured Articles

Johnson & Johnson: Turning supplier spend into local support

Johnson & Johnson’s Global Supplier Diversity & Inclusion team is growing spending with social enterprises around the globe to expand its impact

Seasonal Affective Disorder’s impact on health & solutions

Dr Ravi Gill & Dr. Naomi Newman-Beinart discuss Seasonal Affective Disorder and its treatments, from vitamin D spray to light therapy

CGI teams up with Totalmobile for digital healthcare service

CGI is driving efficiency in healthcare. Hear from Helena Jochberger, at Manufacturing Digital LIVE, a free virtual event on Wednesday 6th December 2023

Deloitte: generative AI can improve access to healthcare

Technology & AI

Wipro & NVIDIA’s revolutionary healthcare uses generative AI

AI & ML

Healthtech platform CoverSelf extends seed round to US$8.2m

Technology & AI